NURS 251 | Pharmacology
OBJECTIVE ASSESSMENT - EXAM
Pharmacology
Final Exam
NURS 251 | Portage Learning
100 100% 2026/2027
QUESTIONS VERIFIED ANSWERS EDITION
TOPICS COVERED
Pharmacokinetics & Pharmacodynamics Antibiotics & Antimicrobial Therapy
Autonomic Nervous System Drugs CNS Drugs & Pain Management
Cardiovascular & Antihypertensive Medications
COVER PAGE - 1
,SECTION 1 | Pharmacokinetics & Pharmacodynamics | Q1-Q20 | Pharmacology NURS 251 Final Exam 2026/2027
Q1 Question 1 of 100
1
A 68-year-old male with chronic kidney disease stage 3 is prescribed a medication that is 90% renally
excreted. The nurse recognizes that the half-life of this drug will be significantly prolonged compared
to a patient with normal renal function. Which pharmacokinetic parameter is most directly affected by
this patient's renal impairment?
A. Clearance
B. Volume of distribution
C. Absorption rate
D. Peak plasma concentration
Correct Answer: A
Rationale:
Clearance is the volume of plasma cleared of drug per unit time and is directly reduced in renal impairment,
leading to drug accumulation. Volume of distribution is more affected by body composition changes, not renal
function directly. Absorption rate and peak concentration are not primarily determined by renal elimination.
Q2 Question 2 of 100
2
A 45-year-old female takes oral levothyroxine every morning on an empty stomach. She begins
taking calcium carbonate with her breakfast and reports worsening fatigue at her 6-week follow-up.
The nurse suspects a drug interaction affecting the bioavailability of levothyroxine. Which
pharmacokinetic phase is primarily impacted by this interaction?
A. Distribution
B. Absorption
C. Metabolism
D. Excretion
Correct Answer: B
Rationale:
Calcium carbonate binds levothyroxine in the gastrointestinal tract, forming an insoluble complex that prevents
absorption across the intestinal mucosa. This interaction occurs during the absorption phase, not distribution,
metabolism, or excretion. Chelation in the gut lumen reduces the amount of drug available for systemic
circulation.
Pharmacology NURS 251 Final Exam — 2026/2027 | Passing Score: 75% | Page 2
1 of 52
,Q3 Question 3 of 100
3
A 52-year-old male with atrial fibrillation is started on warfarin. The nurse explains that it takes several
days to achieve full anticoagulant effect because warfarin inhibits synthesis of new clotting factors but
does not affect those already circulating. This delay in therapeutic effect is best explained by which
pharmacodynamic concept?
A. Tolerance
B. First-pass effect
C. Steady-state kinetics related to clotting factor half-lives
D. Bioavailability
Correct Answer: C
Rationale:
Warfarin's delayed onset is due to the time required for existing vitamin K-dependent clotting factors (with
half-lives of 6-60 hours) to degrade naturally while new synthesis is blocked. This is a pharmacodynamic
concept related to the physiological half-lives of the target proteins, not tolerance, first-pass effect, or
bioavailability.
Q4 Question 4 of 100
4
A 34-year-old female with epilepsy is prescribed phenytoin. Laboratory results show a serum albumin
level of 2.2 g/dL due to malnutrition. The nurse understands that the free (unbound) phenytoin level
will be higher than expected for a given total phenytoin concentration. Which pharmacokinetic
principle explains this phenomenon?
A. First-pass metabolism
B. Enterohepatic recirculation
C. Prodrug activation
D. Protein binding displacement
Correct Answer: D
Rationale:
Phenytoin is highly protein-bound (approximately 90%), and hypoalbuminemia reduces the number of binding
sites, increasing the free drug fraction. This protein binding displacement means total drug levels underestimate
the pharmacologically active concentration. First-pass metabolism, enterohepatic recirculation, and prodrug
activation are unrelated to this effect.
Pharmacology NURS 251 Final Exam — 2026/2027 | Passing Score: 75% | Page 3 of 52
, Q5 Question 5 of 100
5
A 60-year-old male with liver cirrhosis is prescribed a drug that undergoes extensive first-pass
hepatic metabolism. The nurse anticipates that the oral bioavailability of this medication will be
significantly increased. Which best explains why first-pass metabolism is reduced in this patient?
A. Decreased hepatic enzyme activity and portosystemic shunting
B. Increased gastric emptying rate
C. Enhanced cytochrome P450 function
D. Reduced renal clearance of metabolites
Correct Answer: A
Rationale:
Liver cirrhosis reduces functional hepatocyte mass and creates portosystemic shunts that bypass the liver, both
of which decrease first-pass metabolism and increase oral bioavailability. Increased gastric emptying and
enhanced CYP function would not increase bioavailability. Renal clearance of metabolites is unrelated to
first-pass metabolism.
Q6 Question 6 of 100
6
A nurse is teaching a patient about a new medication that has a narrow therapeutic index. The
patient asks what this means. Which statement by the nurse is most accurate?
A. The drug has a wide safety margin between therapeutic and toxic doses.
B. The dose required for therapeutic effect is close to the dose that causes toxicity.
C. The medication reaches peak plasma levels rapidly after administration.
D. The drug is eliminated almost entirely by the kidneys.
Correct Answer: B
Rationale:
A narrow therapeutic index means the effective dose and the toxic dose are very close, requiring careful dose
titration and monitoring. A wide safety margin describes a wide therapeutic index. Peak plasma timing and renal
elimination are unrelated to the concept of therapeutic index.
Pharmacology NURS 251 Final Exam — 2026/2027 | Passing Score: 75% | Page 4 of 52
OBJECTIVE ASSESSMENT - EXAM
Pharmacology
Final Exam
NURS 251 | Portage Learning
100 100% 2026/2027
QUESTIONS VERIFIED ANSWERS EDITION
TOPICS COVERED
Pharmacokinetics & Pharmacodynamics Antibiotics & Antimicrobial Therapy
Autonomic Nervous System Drugs CNS Drugs & Pain Management
Cardiovascular & Antihypertensive Medications
COVER PAGE - 1
,SECTION 1 | Pharmacokinetics & Pharmacodynamics | Q1-Q20 | Pharmacology NURS 251 Final Exam 2026/2027
Q1 Question 1 of 100
1
A 68-year-old male with chronic kidney disease stage 3 is prescribed a medication that is 90% renally
excreted. The nurse recognizes that the half-life of this drug will be significantly prolonged compared
to a patient with normal renal function. Which pharmacokinetic parameter is most directly affected by
this patient's renal impairment?
A. Clearance
B. Volume of distribution
C. Absorption rate
D. Peak plasma concentration
Correct Answer: A
Rationale:
Clearance is the volume of plasma cleared of drug per unit time and is directly reduced in renal impairment,
leading to drug accumulation. Volume of distribution is more affected by body composition changes, not renal
function directly. Absorption rate and peak concentration are not primarily determined by renal elimination.
Q2 Question 2 of 100
2
A 45-year-old female takes oral levothyroxine every morning on an empty stomach. She begins
taking calcium carbonate with her breakfast and reports worsening fatigue at her 6-week follow-up.
The nurse suspects a drug interaction affecting the bioavailability of levothyroxine. Which
pharmacokinetic phase is primarily impacted by this interaction?
A. Distribution
B. Absorption
C. Metabolism
D. Excretion
Correct Answer: B
Rationale:
Calcium carbonate binds levothyroxine in the gastrointestinal tract, forming an insoluble complex that prevents
absorption across the intestinal mucosa. This interaction occurs during the absorption phase, not distribution,
metabolism, or excretion. Chelation in the gut lumen reduces the amount of drug available for systemic
circulation.
Pharmacology NURS 251 Final Exam — 2026/2027 | Passing Score: 75% | Page 2
1 of 52
,Q3 Question 3 of 100
3
A 52-year-old male with atrial fibrillation is started on warfarin. The nurse explains that it takes several
days to achieve full anticoagulant effect because warfarin inhibits synthesis of new clotting factors but
does not affect those already circulating. This delay in therapeutic effect is best explained by which
pharmacodynamic concept?
A. Tolerance
B. First-pass effect
C. Steady-state kinetics related to clotting factor half-lives
D. Bioavailability
Correct Answer: C
Rationale:
Warfarin's delayed onset is due to the time required for existing vitamin K-dependent clotting factors (with
half-lives of 6-60 hours) to degrade naturally while new synthesis is blocked. This is a pharmacodynamic
concept related to the physiological half-lives of the target proteins, not tolerance, first-pass effect, or
bioavailability.
Q4 Question 4 of 100
4
A 34-year-old female with epilepsy is prescribed phenytoin. Laboratory results show a serum albumin
level of 2.2 g/dL due to malnutrition. The nurse understands that the free (unbound) phenytoin level
will be higher than expected for a given total phenytoin concentration. Which pharmacokinetic
principle explains this phenomenon?
A. First-pass metabolism
B. Enterohepatic recirculation
C. Prodrug activation
D. Protein binding displacement
Correct Answer: D
Rationale:
Phenytoin is highly protein-bound (approximately 90%), and hypoalbuminemia reduces the number of binding
sites, increasing the free drug fraction. This protein binding displacement means total drug levels underestimate
the pharmacologically active concentration. First-pass metabolism, enterohepatic recirculation, and prodrug
activation are unrelated to this effect.
Pharmacology NURS 251 Final Exam — 2026/2027 | Passing Score: 75% | Page 3 of 52
, Q5 Question 5 of 100
5
A 60-year-old male with liver cirrhosis is prescribed a drug that undergoes extensive first-pass
hepatic metabolism. The nurse anticipates that the oral bioavailability of this medication will be
significantly increased. Which best explains why first-pass metabolism is reduced in this patient?
A. Decreased hepatic enzyme activity and portosystemic shunting
B. Increased gastric emptying rate
C. Enhanced cytochrome P450 function
D. Reduced renal clearance of metabolites
Correct Answer: A
Rationale:
Liver cirrhosis reduces functional hepatocyte mass and creates portosystemic shunts that bypass the liver, both
of which decrease first-pass metabolism and increase oral bioavailability. Increased gastric emptying and
enhanced CYP function would not increase bioavailability. Renal clearance of metabolites is unrelated to
first-pass metabolism.
Q6 Question 6 of 100
6
A nurse is teaching a patient about a new medication that has a narrow therapeutic index. The
patient asks what this means. Which statement by the nurse is most accurate?
A. The drug has a wide safety margin between therapeutic and toxic doses.
B. The dose required for therapeutic effect is close to the dose that causes toxicity.
C. The medication reaches peak plasma levels rapidly after administration.
D. The drug is eliminated almost entirely by the kidneys.
Correct Answer: B
Rationale:
A narrow therapeutic index means the effective dose and the toxic dose are very close, requiring careful dose
titration and monitoring. A wide safety margin describes a wide therapeutic index. Peak plasma timing and renal
elimination are unrelated to the concept of therapeutic index.
Pharmacology NURS 251 Final Exam — 2026/2027 | Passing Score: 75% | Page 4 of 52
